Experimental Peptide Drug NVG-291 Shows Promise in Phase 2 Trial for Spinal Cord Injury Recovery
核心洞察
NVG-291, an injectable peptide drug, demonstrated significant mobility improvements in a phase 2 trial for spinal cord injury (搜索) patients, with one participant reducing his 10-meter walk time from 45 to 15 seconds.
The drug works by blocking inhibitory signals that prevent nerve fiber regrowth after spinal cord injury (搜索), potentially enhancing neuron growth and nervous system (搜索) repair.
Patient Larry Williams continues to show sustained improvements over a year after completing the three-month treatment, including the ability to balance on one foot for 30 seconds.
A phase 2 clinical trial testing the experimental peptide drug NVG-291 has shown promising results for patients with spinal cord injuries, with participants demonstrating significant improvements in mobility and motor function. The injectable treatment represents a novel approach to addressing a condition that currently has no FDA-approved therapeutic options.
Trial Results and Patient Outcomes
Larry Williams, a 58-year-old trial participant from Philadelphia, experienced remarkable recovery after sustaining a severe spinal cord injury (搜索) from a mountain biking accident. Williams suffered fractures to his C4-C6 vertebrae after striking a tree, resulting in initial paralysis despite wearing a helmet. Following spinal surgery, he remained paralyzed for two weeks before beginning to regain some movement through therapy.
During the three-month trial period starting in April 2024, Williams received daily NVG-291 injections followed by one hour of physical therapy, including hand exercises and walking with a harness on a flat track or treadmill. The treatment protocol also included monthly blood tests, electrophysiological testing to measure nerve and muscle electrical activity, and physical assessments.
At the trial's conclusion, Williams achieved a significant improvement in his 10-meter walk test, completing the distance with walker assistance in 15 seconds compared to his baseline time of 45 seconds. More than a year after completing treatment in July 2024, Williams continues to experience ongoing improvements without additional drug administration or intensive therapy.
"I'm not working out really hard. I'm currently not in therapy," Williams reported. "But just a couple of days ago, I stood up and tried to free-stand, balance and lift one foot off the ground. I was able to do it for 30 seconds." This represents a dramatic improvement from six months earlier when he couldn't maintain the same position for even three seconds.
Mechanism of Action
Dr. Monica Perez, scientific chair at the Shirley Ryan AbilityLab in Chicago and professor of physical medicine and rehabilitation at Northwestern University, led the research team. The drug was initially tested in animal models, which demonstrated improved locomotor function before advancing to human trials.
NVG-291 is a peptide that functions as a repair molecule designed to improve nervous system (搜索) function. The drug works by blocking inhibitory signals that the body naturally produces after spinal cord injury (搜索), which normally prevent nerve fiber regrowth. "This peptide can block those inhibitory signals," Perez explained. "There is a little bit of evidence in animals that it can actually enhance the growth of neurons (搜索)."
The randomized clinical trial design included a control group receiving placebo, with half of participants receiving the active NVG-291 treatment. Researchers observed "strong electrophysiological changes in the group that received the medication compared to the placebo group," according to Perez.
Treatment Advantages and Safety Profile
Unlike traditional approaches to spinal cord injury (搜索) treatment, which typically involve cell therapies such as stem cells and bone marrow stromal cells, the peptide approach offers several practical advantages. Perez noted that NVG-291 is "easy to administer," can be administered at home, achieves a "similar goal" to more complex therapies, and is "extremely safe."
The treatment's mechanism differs significantly from other peptide-based drugs currently in clinical use. While GLP-1 receptor agonists represent another class of peptide therapeutics primarily used for weight loss and diabetes treatment, NVG-291 has a distinct mechanism focused specifically on neural repair and regeneration.
Sustained Recovery and Future Implications
Williams' continued improvement more than a year after treatment completion suggests potential long-lasting effects of the therapy. He has progressed to swimming laps and performing various physical tasks with increased ease and fluidity. "The movement in my legs seems to be a little bit smoother and less restricted as the time passed by," he reported.
However, researchers acknowledge significant knowledge gaps regarding treatment duration and long-term efficacy. "We don't have follow-up measurements," Perez stated. "There's no way for us to understand the real duration of these treatments."
The absence of FDA-approved treatments for spinal cord injuries underscores the potential significance of this research. Perez emphasized that the research team remains "very devoted" to advancing this science given the substantial unmet medical need.
Williams, who lost 40 pounds following his accident and initially required walker assistance for limited mobility, now advocates for broader access to the treatment. "It could really change things for people with injuries like mine," he said. "I'm just praying that everybody out there is able to have an opportunity to gain back their life."